Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4809 | vv-ECMO + cytokine adsorption (Cytosorb adsorber) Wiki | 1.00 |
| drug2897 | Physical Exercises Wiki | 0.71 |
| drug2173 | Lopinavir/Ritonavir 400 mg/100 mg Wiki | 0.71 |
Navigate: Correlations HPO
There are 2 clinical trials
In December 2019 in the city of Wuhan in China, a series of patients with unclear pneumonia was noticed, some of whom have died of it. In virological analyses of samples from the patients' deep respiratory tract, a novel coronavirus was isolated (SARS-CoV-2). The disease spread rapidly in the city of Wuhan at the beginning of 2020 and soon beyond in China and, in the coming weeks, around the world. Initial studies described numerous severe courses, particularly those associated with increased patient age and previous cardiovascular, metabolic and respiratory diseases. A small number of the particularly severely ill patients required not only highly invasive ventilation therapy but also extracorporeal membrane oxygenation (vv-ECMO) to supply the patient's blood with sufficient oxygen. Even under maximum intensive care treatment, a very high mortality rate of approximately 80-100% was observed in this patient group. In addition, high levels of interleukin-6 (IL-6) could be detected in the blood of these severely ill patients, which in turn were associated with poor outcome. From experience in the therapy of severely ill patients with severe infections and respiratory failure, we know that treatment with a CytoSorb® adsorber can lead to a reduction of the circulating pro- and anti-inflammatory cytokines and thus improve the course of the disease and the outcome of the patients. Our primary goal is to investigate the efficacy of treatment with a CytoSorb® adsorber in patients with severe COVID-19 disease requiring venous ECMO over 72 hours after initiation of ECMO. The primary endpoint is the reduction of plasma interleukin-6 levels 72 hours after initiation of ECMO support. As secondary endpoints we investigate 30-day survival, vasopressor and volume requirements, lactate in terms of lactate and platelet function. As safety variables, we further investigate the levels of the applied antibiotics (usually ampicillin and sulbactam).
Description: measurement of IL-6 levels in patient blood after 72 hours of cytokine adsorption (in relation to level before initiation of cytokine adsorption)
Measure: interleukin-6 (IL-6) level after 72 hours Time: 72 hoursDescription: survival after 30 days
Measure: 30-day-survival Time: 72 hoursDescription: needed dosage of norepinephrine and other vasopressors
Measure: vasopressor dosage Time: 72 hoursDescription: fluid balance levels during cytokine adsorption
Measure: fluid balance Time: 72 hoursDescription: serum-lactate levels during cytokine adsorption
Measure: lactate Time: 72 hoursIn December 2019 in the city of Wuhan in China, a series of patients with unclear pneumonia was noticed, some of whom have died of it. In virological analyses of samples from the patients' deep respiratory tract, a novel coronavirus was isolated (SARS-CoV-2). The disease spread rapidly in the city of Wuhan at the beginning of 2020 and soon beyond in China and, in the coming weeks, around the world. Initial studies described numerous severe courses, particularly those associated with increased patient age and previous cardiovascular, metabolic and respiratory diseases. A small number of the particularly severely ill patients required not only highly invasive ventilation therapy but also extracorporeal membrane oxygenation (vv-ECMO) to supply the patient's blood with sufficient oxygen. Even under maximum intensive care treatment, a very high mortality rate of approximately 80-100% was observed in this patient group. In addition, high levels of interleukin-6 (IL-6) could be detected in the blood of these severely ill patients, which in turn were associated with poor outcome. From experience in the therapy of severely ill patients with severe infections and respiratory failure, we know that treatment with a CytoSorb® adsorber can lead to a reduction of the circulating pro- and anti-inflammatory cytokines and thus improve the course of the disease and the outcome of the patients. The aim of the study is to investigate the influence of extracorporeal cytokine adsorption on interleukin-6-levels and time to successful ECMO explantation under controlled conditions in patients with particularly severe COVID-19 disease requiring extracorporeal membrane oxygenation.
Description: measurement of IL-6 levels in patient blood after 72 hours of cytokine adsorption (in relation to level before initiation of cytokine adsorption)
Measure: IL-6 reduction by 75% or more after 72 hours as compared to the baseline measurement Time: 72 hoursDescription: time to successful ECMO-explantation within 30 days after randomization
Measure: time to successful ECMO-explantation Time: 30 daysDescription: Ventilator free days (VFD) in the first 30 days after randomization, where invasive mechanical ventilation (IMV), non-invasive ventilation (NIV) and ECMO are defined as ventilator days. VFD=0, if the patient dies in the first 30 days after randomization
Measure: Ventilator free days (VFD) Time: 30 daysDescription: Time to extubation from ventilation and explantation from ECMO. Death under ventilation and/or ECMO will be analyzed as a competing event. The time will be censored at the time of last visit for surviving patients under ventilation and/or ECMO.
Measure: Time to extubation from ventilation and explantation from ECMO Time: 30 daysDescription: Overall survival time, defined as time from randomization to death. The time will be censored at the time of last visit for surviving patients.
Measure: Overall survival time Time: 30 daysDescription: Days on intensive care unit (ICU)
Measure: Days on intensive care unit (ICU) Time: 30 daysDescription: Vasopressor dosage of adrenaline, noradrenaline, vasopressin, and dobutamine at 24, 48,72 h
Measure: Vasopressor dosage Time: 24, 48, 72 hoursDescription: Total fluid[ml] substitution and fluid balance [ml] at 24, 48, 72 h
Measure: Fluid substitution and fluid balance Time: 24, 48, 72 hoursDescription: Serum lactate at 24, 48, 72 h
Measure: Serum lactate Time: 24, 48, 72 hoursDescription: Urine output at 24, 48, 72 h
Measure: Urine output Time: 24, 48, 72 hoursDescription: Willebrand factor at 24, 48, 72 h
Measure: Willebrand factor Time: 24, 48, 72 hoursDescription: d-dimers at 24, 48, 72 h
Measure: d-dimers Time: 24, 48, 72 hoursDescription: interleukin-6 levels at 24, 48, 72 h
Measure: interleukin-6 levels Time: 24, 48, 72 hoursDescription: Sequential Organ Failure Assessment Score at 24, 48, 72 h (values from 6 to 24, where the higher values explain higher disease severity)
Measure: SOFA-Score Time: 24, 48, 72 hoursDescription: serious complications or malfunctions related to the CytoSorb device
Measure: serious adverse device effects Time: 30 daysDescription: unintended air in the ECMO system during operation of the device
Measure: adverse event of special interest: air in the ECMO system Time: 30 daysDescription: unintended blood-clotting in the ECMO system during operation of the device
Measure: adverse event of special interest: blood-clotting in the ECMO system Time: 30 daysDescription: major bleeding events
Measure: adverse event of special interest: bleeding complications Time: 30 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports